Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a breakthrough therapy designation from the National Medical Products Administration for its injectable drug SHR-A1811, marking the 10th indication for this drug to receive such certification [1] Group 1 - The drug SHR-A1811 is indicated for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring HER2 (ERBB2) activating mutations [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation for its injectable SHR-A1811, marking the tenth indication for this drug [1] Group 1: Product Development - The injectable SHR-A1811 has been approved for domestic market launch in May 2025, targeting adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy [1] - The cumulative R&D investment for the injectable SHR-A1811 project has reached approximately 1.7725 billion yuan (unaudited) [1] Group 2: Market Potential - According to EvaluatePharma database, the global sales for similar products are projected to total approximately 6.557 billion USD by 2024 [1]

Core Viewpoint - The company’s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, indicating significant progress in its development [1] Group 1: Product Development - HRS-5346 is an oral small molecule inhibitor targeting elevated lipoprotein(a) [Lp(a)] levels, which is a common single-gene lipid disorder and a typical manifestation of lipoprotein dysregulation [1] - Currently, there are no similar products approved for market release domestically or internationally, highlighting the uniqueness of HRS-5346 [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5346 project has reached approximately 76.3 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The indication for SHR-1826 is proposed for monotherapy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer who have failed at least one line of systemic therapy and have c-Met overexpression (2-3+, ≥50%) [1]

Group 1 - The core point of the article is that Heng Rui Medicine's injectable SHR-1826 has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 2 - The announcement was made by Heng Rui Medicine, specifically through its subsidiary Suzhou Sediya Biopharmaceutical Co., Ltd [1]

Core Viewpoint - The company’s subsidiary, Zhejiang Daor Biological Technology Co., Ltd., has developed a first-in-class long-acting tri-target agonist, DR10624, which has been included in the breakthrough therapy category for the treatment of severe hypertriglyceridemia (sHTG) [1][2]. Drug Information - Drug Name: DR10624 Injection - Registration Category: Class 1 Biologic Product - Acceptance Number: CXSB2300148 - Indication: Severe hypertriglyceridemia - Reason for Inclusion: The drug meets the criteria for breakthrough therapy as per the regulatory guidelines [1]. R&D and Registration Status - DR10624 is a globally innovative tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, with clinical research approvals from China CDE and the US FDA expected in October 2023 and October 2025, respectively [2]. - The Phase II clinical study (DR10624-201) results are set to be presented at the AHA Scientific Sessions 2025, showcasing significant triglyceride (TG) reductions: 74.5% in the 12.5mg group, 66.2% in the 25mg group, and 68.9% in the 50mg titration group [2]. - 78.5% of participants in the treatment group experienced TG reductions exceeding 50%, and 89.5% had TG levels below 500 mg/dL [2]. - DR10624 also demonstrated efficacy in improving lipid profiles related to atherosclerosis and significantly reducing liver fat content, with a median percentage reduction of up to 67% [2]. Clinical Advantages - DR10624 exhibits strong lipid-lowering effects and good safety profiles, making it a promising treatment option for sHTG patients [3]. - The drug's ability to lower liver fat and regulate metabolic syndromes adds to its clinical value [3]. Market Context - The prevalence of sHTG is increasing, with approximately 10% of adults affected globally, and 1% suffering from severe cases [4]. - Traditional lipid-lowering medications have limited efficacy in reducing TG levels below 500 mg/dL, highlighting the need for innovative treatments like DR10624 [5]. - The public health threat posed by sHTG is gaining attention, necessitating better therapeutic options [5]. Future Considerations - Following its inclusion in the breakthrough therapy list, DR10624 must complete further clinical trials and receive regulatory approval before market launch [4]. - The drug development process is characterized by high investment, long timelines, and significant risks, with various factors influencing clinical trial outcomes and market competition [4].

Core Viewpoint - The announcement highlights that East China Pharmaceutical's subsidiary, Zhejiang Daor Biotechnology, has developed a groundbreaking drug, DR10624, which has been included in the list of breakthrough therapies for severe hypertriglyceridemia (sHTG) by the National Medical Products Administration (NMPA) of China [1][4]. Drug Information - Drug Name: DR10624 Injection - Registration Category: Class 1 Biopharmaceutical - Acceptance Number: CXSB2300148 - Indication: Severe hypertriglyceridemia (sHTG) [1]. R&D and Registration Status - DR10624 is a globally innovative long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, with clinical research approvals from both China CDE and the US FDA for sHTG [2]. - The Phase II clinical study (DR10624-201) results showed significant triglyceride (TG) reductions: 74.5% in the 12.5mg group, 66.2% in the 25mg group, and 68.9% in the 50mg titration group [2]. - 78.5% of participants experienced TG reductions exceeding 50%, and 89.5% had TG levels below 500 mg/dL [2]. - DR10624 also demonstrated significant improvements in lipid profiles and liver fat content, with a median percentage reduction of up to 67% in liver fat [2][3]. Clinical Advantages - DR10624's innovative tri-target mechanism provides strong lipid-lowering effects and good safety profiles, making it a promising treatment option for sHTG patients [3]. - The drug's efficacy in reducing liver fat and regulating metabolic syndrome is highlighted as a significant clinical advantage [3]. Market Context - sHTG, defined as TG levels exceeding 500 mg/dL, poses significant health risks, including cardiovascular diseases and pancreatitis, with a rising prevalence globally [4]. - Traditional lipid-lowering medications have limited efficacy in reducing TG levels below 500 mg/dL, indicating a clinical need for more effective treatments like DR10624 [4]. Future Steps - Following its inclusion in the breakthrough therapy list, DR10624 must complete further clinical trials and receive approval from the NMPA before market launch [5]. - The company is committed to advancing the drug's development in accordance with national regulations and will keep investors informed of progress [5].

Major Events - Defu Technology announced the termination of the acquisition of 100% equity in Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy, with a contract deposit of €17.4047 million to be fully refunded within 10 working days after termination [1] - China Nonferrous Mining expects a total copper production of approximately 484,000 tons in 2026, including 134,000 tons of cathode copper and 350,000 tons of crude/anode copper, with a decrease in crude/anode copper production due to planned maintenance [3] - Huadong Medicine's subsidiary, Zhejiang Daor Biotechnology, has its DR10624 injection included in the breakthrough therapy designation list for severe hypertriglyceridemia, with clinical research approvals from China CDE and the US FDA [4] Performance - Xiantan Co. reported chicken product sales revenue of CNY 530 million in December 2025, with a year-on-year increase of 9.41% and a sales volume of 55,100 tons [5] - Jinzizi Liquor expects to report a net loss for the fiscal year 2025, although the loss is anticipated to narrow compared to the previous year [6] - Dechang Co. forecasts a net profit of CNY 160 million to CNY 200 million for 2025, representing a year-on-year decrease of 51% to 61% [7] Stock Suspension and Resumption - Jiamei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, leading to a temporary suspension for investigation [8] - Yanjing Co. continues to suspend trading due to uncertainties related to asset acquisition plans, with an expected disclosure of the transaction plan by January 19, 2026 [9]

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting tri-target agonist, DR10624, which has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of severe hypertriglyceridemia (sHTG) [1] Group 1 - The long-acting tri-target agonist DR10624 targets three receptors: Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-like Peptide-1 Receptor (GLP-1R) [1]